Phenotypic assays using human primary cells are highly valuable tools for target discovery and validation in drug discovery. Expression knockdown (KD) of such targets in these assays allows the investigation of their role in models of disease processes. Therefore, efficient and fast modes of protein KD in phenotypic assays are required. The CRISPR/Cas9 system has been shown to be a versatile and efficient means of gene inactivation in immortalized cell lines. Here we describe the use of adenoviral (AdV) CRISPR/Cas9 vectors for efficient gene inactivation in two human primary cell types, normal human lung fibroblasts and human bronchial epithelial cells. The effects of gene inactivation were studied in the TGF-β-induced fibroblast to myofibroblast transition assay (FMT) and the epithelial to mesenchymal transition assay (EMT), which are SMAD3 dependent and reflect pathogenic mechanisms observed in fibrosis. Co-transduction (co-TD) of AdV Cas9 with SMAD3-targeting guide RNAs (gRNAs) resulted in fast and efficient genome editing judged by insertion/deletion (indel) formation, as well as significant reduction of SMAD3 protein expression and nuclear translocation. This led to phenotypic changes downstream of SMAD3 inhibition, including substantially decreased alpha smooth muscle actin and fibronectin 1 expression, which are markers for FMT and EMT, respectively. A direct comparison between co-TD of separate Cas9 and gRNA AdV, versus TD with a single "all-in-one" Cas9/gRNA AdV, revealed that both methods achieve similar levels of indel formation. These data demonstrate that AdV CRISPR/Cas9 is a useful and efficient tool for protein KD in human primary cell phenotypic assays. The use of AdV CRISPR/Cas9 may offer significant advantages over the current existing tools and should enhance target discovery and validation opportunities.
Introduction
First-in-class drug discovery generally starts with the identification of novel targets in a relevant disease model, by pinpointing which genes contribute to a specific biological process or disease [1] . Phenotypic assays with human primary cells in combination with reduction of gene expression ("knockdown", KD) are a valuable tool to explore the function of targets in PLOS ONE | https://doi.org/10.1371/journal.pone.0182974 August 11, 2017 1 / 20 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 the use of immortalized cells, which have the advantage of allowing for easy selection strategies and cloning of edited cells. However, these cells are generally very different from their original source (i.e. primary cells), due to their transformation status. So far only few studies have applied CRISPR/Cas9 to human primary cells, most likely in part because of their limited lifespan, which is restrictive for selection and enrichment strategies. Nevertheless, successful gene editing in human primary cells without drug selection has been reported in cell types such as CD4+ T-lymphocytes, dermal fibroblasts, (pre)adipocytes, endothelial cells, and airway epithelial cells [15] [16] [17] [18] [19] . It is likely that this can be extended to other human primary cell types as well. However, for beneficial use of genomic editing in short-lived phenotypic assays for drug discovery with primary cells, the method needs to be comparably fast, efficient and specific as RNAi.
To assess the use of an AdV-based CRISPR/Cas9 platform for target discovery and/or validation, we applied AdV TD of Cas9 and gRNA components in human primary cell models of fibrosis, focusing on the transforming growth factor (TGF)-β signaling pathway. It is demonstrated that AdV delivery of Cas9 endonuclease and gRNA lead to highly efficient editing of the SMAD3 gene ("Mothers against decapentaplegic homolog 3") in both, normal human lung fibroblasts (NHLFs) and human bronchial epithelial cells (HBECs). Delivery of Cas9 and gRNA by two separate AdVs results in similar genomic editing efficiencies when compared with a single all-in-one AdV particle containing both Cas9 and gRNA. CRISPR/Cas9-mediated editing results in very effective SMAD3 protein KD and, as a consequence, inhibits fibroblast to myofibroblast transition (FMT) and epithelial to mesenchymal transition (EMT) in NHLF and HBEC primary cell phenotypic assays, respectively. This suggests that the AdV-based CRISPR/Cas9 platform is a valuable tool to study gene function in human primary cells, which may hold great promise for the identification of novel drug targets.
Materials and methods

Ethics statement
The research described here has been performed according to applicable Dutch national ethics regulations and was conducted within Galapagos B.V. Galapagos' scientists are qualified to perform research with these human materials and Galapagos makes available appropriate facilities and equipment to allow such scientists to comply with applicable laws, regulations and internal rules applicable to the use, handling and storage of the material. The human material was obtained from Epithelix Sàrl (Switzerland) and from Tissue Solutions Ltd (Scotland). Both suppliers have confirmed to Galapagos that they received informed consent from the donors to use the material for research purposes. The genetic modification of these cells as described was conducted according to permits from the Dutch authorities (reference number IG-16-019_IIk). The cells were used exclusively for target and drug discovery and were not used for human experimentation or therapy. All material is and will remain anonymized at all times.
Cells and phenotypic assays
NHLFs were acquired from Epithelix Sàrl, Switzerland. HBECs were obtained from lung and bronchial resection tissue of patients diagnosed with idiopathic pulmonary fibrosis undergoing surgery for lung transplantation (Tissue Solutions Ltd, Scotland). HBECs were isolated by protease digestion as previously described [20] . NHLF cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Life Technologies), 100 units/mL of penicillin and 100 μg/mL of streptomycin ("Pen-Strep", Gibco). For the FMT assay, NHLFs were seeded in 96 well plates coated with 3 μg/mL PureCol (Advanced Biomatrix) at a density of 3,000 cells per well and kept in DMEM supplemented with 2% FBS and Pen-Strep. Cells were transduced with AdV on day in vitro (DIV) 1 and refreshed on DIV 2. Cells were triggered with 2 ng/mL TGF-β1 (R&D Systems) dissolved in DMEM supplemented with 0.2% FBS and Pen-Strep on DIV 6. For the EMT assay, HBECs were cultured in Keratinocyte serum-free medium (KSFM) supplemented with 0.2 ng/mL epidermal growth factor (EGF) and 25 μg/mL bovine pituitary extract (BPE), 1 μM isoproterenol and Pen-Strep (all from Gibco). During maintenance HBECs were grown on surfaces coated with 10 μg/mL fibronectin 1 (Sigma-Aldrich), 30 μg/mL PureCol and 10 μg/ mL bovine serum albumin (BSA). For the assay HBECs were seeded in 96 well plates coated with 30 μg/mL PureCol at a density of 2,500 cells per well and transduced with AdV on DIV 1, followed by refreshment on DIV 2. Triggering was performed with 0.5 ng/mL TGF-β1 and 5 ng/mL TNFα (tumor necrosis factor alpha, R&D Systems) dissolved in KSFM growth medium on DIV 6. NHLF cells and HBECs were maintained at 37˚C and 5% CO 2 and refreshed twice after thawing of the cells.
The E1-and E2A-complementing AdV packaging cell line PER.C6/E2A was cultured in DMEM supplemented with 10% FBS, 10 mM MgCl 2 and 250 mg/mL Geneticin (Life Technologies). Geneticin was only used during the first two passages to remove PER.C6 cells without the E2A gene. PER.C6/E2A cells were sub-cultured every 3 to 4 days by seeding 10 7 cells in a T175 flask containing 25 mL growth medium. Cells were maintained at 39˚C and 10% CO 2 and were shifted to 34˚C during AdV production to ensure correct folding of their E2A-encoded temperature-sensitive DNA-binding protein.
CRISPR/Cas9 construct design and AdV production
A human codon-optimized Cas9 based on the S. pyogenes wild-type Cas9 sequence was generated by gene synthesis (GeneArt). Guide RNA sequences were adapted from Jinek et al. 2012 [8] . The 19-20 bp target specific gRNA sequences were designed by Sigma-Aldrich. Complementary oligonucleotides containing the gRNA target sequence were ordered from Life Technologies and cloned into AdV adapter plasmids by SapI restriction enzyme digestion (Thermo Scientific). This resulted in removal of a ccdB selection cassette and was followed by ligation of the gRNA-encoding oligonucleotides using T4 DNA ligase (Thermo Scientific). Ligations were transformed into either MultiShot StripWell Mach1 (gRNA only constructs) or MAX Efficiency Stbl2 ("all-in-one" constructs) competent cells (both from Invitrogen). The AsRed reporter-gene construct was adapted from the pAsRed2-C1 vector (Clontech). For nuclear expression of the reporter a 3x NLS sequence (5'-GGAGATCCAAAAAAGAAGAGAAAGGTA GATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAG-GTACTCGAG-3') was cloned directly downstream from the AsRed open reading frame. The AsRed-3xNLS sequence was cloned into an AdV adapter plasmid containing a CMV promoter by standard restriction enzyme digestion and ligation. For the generation of AdVs, the pIPspAdapt-based constructs were transiently transfected in a 96-well format together with AdV helper DNA into the producer cells PER.C6/E2A, seeded at 25,000 cells per well [21, 22] . The produced AdVs were propagated by reinfecting PER.C6/E2A seeded at a density of 50,000 cells per well. During these steps PER.C6/E2A were kept in DMEM supplemented with 10% FBS and 10 mM MgCl 2 . Titers of the crude lysates were determined as described [23] .
Adenoviral TD
Cells were transduced at a multiplicity of infection (MOI) between 2.5 and 80. The total viral load between parallel samples was kept constant at all times to ensure comparable conditions. Crude AdV lysates were diluted in the appropriate cellular growth medium, and 10-20 μL were added to each well of a 96 well plate, or 100-200 μL to each T25 flask.
Cell viability assay
NHLFs and HBECs were seeded in 96 well plates at a density of 3,000 or 2,500 cells per well, respectively. Cells were transduced with AdV on DIV 1 and medium was refreshed on DIV 2. NHLFs and HBECs were triggered on DIV 6 with 2 ng/mL TGF-β1 or 0.5 ng/mL TGF-β1 and 5 ng/mL TNFα, respectively. Cell viability was determined on DIV 9 by adding 20 μL per well CellTiter-Blue 1 Reagent and incubating the cells for 2 hours (HBECs) or 4 hours (NHLFs) at 37˚C and 5% CO 2 prior to measuring fluorescence on an EnVision Multilabel Plate Reader (Perkin Elmer).
Genomic DNA isolation and SURVEYOR ® assay
Efficiency of CRISPR/Cas9-mediated target gene disruption was measured by using mismatch-sensitive SURVEYOR 1 nuclease. To this end, genomic DNA from up to 10 5 cells per sample was isolated using the ZR-96 Quick-gDNA kit (Zymo Research), followed by PCR amplification of a DNA fragment comprising the target site for the appropriate gRNA AdV construct (for sequence information see S1 Table) . PCR amplification was performed using a high fidelity PCR enzyme mix (Thermo Scientific Assay plates were imaged using the IN Cell Analyzer 6000 with a solid state laser (405, 488 nm, 561 nm, 633 nm) and a 2048x2048 pixel sCMOS camera (GE Healthcare). Fluorescent probes were imaged using the appropriate laser line and emission filter and with optimal exposure times for the best signal to noise ratios. Images were analyzed using an algorithm developed in house with the GE Developer software package. Nuclear segmentation was based on DAPI images and used for cell counting. The fibronectin 1 (FN1) or alpha smooth muscle actin (ACTA2) signals were segmented in their respective channels and intensity x area was calculated as a measure of protein expression. Target (SMAD3) protein levels were evaluated using a cytoplasmic mask based on an expanded nuclei segmentation area and intensity x area was determined. Nuclear AsRed signals were evaluated using the nuclear segmentation mask to calculate the number of AsRed positive cells.
Results
TD of AdV-encoded CRISPR/Cas9 components results in highly efficient genomic editing in human primary cells
To date most CRISPR/Cas9 studies have relied on the use of plasmid transfection or LV TD to deliver the Cas9 and gRNA components into the host, in combination with selection of recombined cell populations. Although transfection can be time-saving, it can be difficult to titrate the amount of DNA copies entering each cell. Furthermore, the efficiency of DNA transfection is often limited in primary cells and can lead to significant cell death. Delivery by LV TD may overcome these issues, but LVs can have other unwanted characteristics such as random integration into the host genome. The use of AdV may be superior in this regard as AdV has a linear double stranded genome capped with protein at its 5' ends, which has been reported to be more specific for genome editing [12] . To test this approach, we generated AdV constructs containing either the U6 promoter-driven gRNA or CMV promoter-driven S. pyogenes wild type Cas9 endonuclease component ( Fig 1A) . Since both, gRNA and Cas9 protein are required for the system to work, this requires simultaneous TD of cells with the gRNA and Cas9 AdV, which may be inefficient. Therefore, we also designed an AdV construct encoding gRNA and Cas9 for expression in the same viral particle ("all-in-one"), which allows delivery by a single TD event. The constructs were designed to allow for easy exchange of the 19-20 bp target specific sequence of the gRNAs to simplify future cloning efforts for different genes of interest.
As proof of concept, the SMAD3 gene was targeted using our AdV CRISPR/Cas9 approach. SMAD3 plays an important role in TGF-β dependent signaling from the stimulated receptor (TGF-βR) at the cell surface to the nucleus, regulating transcription of various genes together with other SMAD proteins and transcription factors [25] . Triggering of the TGF-βR pathway results in increased production of extracellular matrix components as well as EMT of epithelial cells. These events are hallmarks of fibrosis. Guide RNA targeting sequences were chosen to be specific for SMAD3 and aimed at all major SMAD3 isoforms ( Fig 1B and S1 Table) . These 19 bp sequences were cloned into AdV adapters using standard restriction enzyme digestion and DNA ligation.
The CRISPR/Cas9 AdV constructs were tested in NHLFs and HBECs, two physiologically relevant human primary cell types, which are implicated in fibrosis in vivo. Initially, co-TD of these cell types with AdV encoding SMAD3-targeting or a non-targeting gRNA and Cas9 AdV was carried out. After 4-7 days the genomic DNA was analyzed for the presence of NHEJderived insertions or deletions (indels) in the target region, using the SURVEYOR relative difference in indel frequency achieved with the three tested SMAD3-specific gRNAs was comparable between HBECs and NHLFs, potentially suggesting a broad applicability of the approach.
To study the effects of SMAD3 genomic editing on functional readouts in human primary cells, we first needed to determine the optimal conditions for editing. To that end, NHLFs were co-transduced with Cas9 and either SMAD3_v39 or non-targeting gRNA AdVs at various MOIs ranging from 2.5-40 for each viral particle. In parallel, NHLFs were transduced with a single all-in-one AdV containing Cas9 plus SMAD3_v39 or non-targeting gRNA at MOIs ranging from 2.5-80. Following TD with the appropriate AdV construct(s) SMAD3 genomic editing was analyzed with the use of the SURVEYOR 1 assay as described earlier. In general, up to the mid-MOI range tested the use of a higher MOI for TD of the NHLFs increased indel formation in the SMAD3 target region (Fig 2A-2D ). This was true for both the co-TD and all- in-one approach. For the comparison of co-TD with the all-in-one AdV, it needs to be taken into account that equal molarities of AdVs will result in higher molar ratios of Cas9 and gRNA, due to the presence of both inserts in one particle. Thus co-TD MOIs of 5 + 5 would carry molar equivalents of all-in-one AdV MOI 5 for both inserts. Interestingly, these two approaches yielded similar levels of indel formation at equimolar levels of insert (S9A Fig). Apart from genomic editing, toxicity was assessed by performing a cell viability assay to determine the AdV MOI which could be relevant for use in functional assays. Delivery of AdV constructs in NHLFs by co-TD or single TD resulted in similar amounts of cellular toxicity which was limited to about 20% for the highest viral load tested (S4 Fig). The TD efficiency in NHLFs was close to 100% already at MOI 10, according to titrations using an AsRed reporter-gene AdV ( S6A Fig) . Therefore, the optimal MOI in NHLFs for Cas9 and gRNA AdVs is expected to be in the range of MOI 10-20 each for functional studies.
Since the optimal condition may be different for each cell type, a similar AdV dose-response curve was generated for the HBECs as well. Due to the higher toxicity in these cells, the viral load range was lowered to MOI 2.5-20 for the co-TD and MOI 2.5-40 for TD with the all-in-one AdV constructs (S5 Fig). Like in NHLF cells, NHEJ-derived indel formation in the SMAD3 gene was increased with higher viral load used for delivery of Cas9 and gRNA (Fig 3A-3D) . A plateau was reached in the mid-MOI range for the co-TD approach, but was less evident for the all-in-one system. Generally speaking, co-TD of HBECs with Cas9 and SMAD3_v39 gRNA AdVs or TD with all-in-one SMAD3_v39 AdV resulted in comparable genomic editing levels at equimolar levels of insert (S9B Fig). The all-in-one system may, however, perform somewhat better than the co-TD approach especially at the lower MOI range. This advantage may be offset by slightly higher toxicity of the all-in-one system versus co-TD though (see S4 and S5 Figs). Remarkably, the overall efficiency of indel formation in HBECs at lower total MOI compared to NHLFs was similar, although TD-efficiencies appeared significantly lower for HBECs when tested with AsRed reporter AdV (S6B Fig). Taking these data into account, we predict the optimal MOI for Cas9 and gRNA AdVs in HBECs to be lower than that used for the NHLFs to enable functional readouts. To summarize, these data demonstrate that AdV delivery of CRISPR/Cas9 components results in very efficient gene interference in human primary cells, without the need for selection or enrichment of edited cells.
AdV-delivered CRISPR/Cas9 components result in effective depletion of SMAD3 protein in human primary cells DNA double strand breaks generated by the wild type Cas9 protein complexed with non-coding gRNA are repaired by the error-prone NHEJ pathway in most cases. This will lead to indels in the target region, which may or may not interfere with expression of the target gene. In general, indels generated by the NHEJ repair pathway should result in a frameshift in the open reading frame in two-thirds of the cases. Very often this will lead to KO of full-length protein expression, as a premature stop codon is generated, causing either expression of a truncated, non-functional protein or degradation of the mRNA by the nonsense-mediated decay pathway [26] . Although high frequencies of indel formation were obtained in the targeted SMAD3 genomic region using AdV delivery of CRISPR/Cas9 components, this may not necessarily be reflected on the protein level, which is most relevant for phenotypic assays. Therefore, the protein expression level of SMAD3 in NHLFs and HBECs was assessed following co-TD with Cas9 and one of the SMAD3-specific gRNAs (v39), which was most effective in generating indels. On DIV 12 after co-TD, cells were harvested for genomic DNA analysis as well as protein analysis. As seen previously, efficient disruption of the targeted SMAD3 gene was observed, given the level of indel formation in both cell types (Fig 4A) . Analysis of protein lysates from these cells by immunoblotting revealed highly efficient depletion of SMAD3 protein after co-TD with Cas9 and SMAD3-targeting gRNA (Fig 4B) . In contrast, TD of the cells with Cas9 alone or in combination with control gRNA AdV did not lead to a specific reduction in SMAD3 protein levels correlated with indel formation, although SMAD3 protein levels appear to be non-specifically reduced by AdV TD in NHLFs, but not HBECs. This does not seem to be related to Cas9 expression, but is a general effect caused by AdV TD (S7 Fig). The specific effect on SMAD3 protein expression is reproducible in both cell types and has been observed in two independent experiments. Detection of Cas9 and β-actin protein as loading control on the immunoblots suggests equal loading of samples and strong presence of Cas9 when expressed. The efficient depletion of SMAD3 protein following AdV co-TD of Cas9 and SMAD3-specific gRNA is reflected in quantification of the SMAD3 signals by densitometry (Fig 4C) . The effect was most noticeable in HBECs, where almost 90% reduction was seen. Although less pronounced in NHLF cells, about 60% reduction in SMAD3 expression is 
The AdV CRISPR/Cas9 platform is a valuable tool for application in phenotypic assays
To explore its use for target identification and/or validation, the AdV CRISPR/Cas9 platform was applied to phenotypic assays, which mimic some molecular aspects observed in fibrosis. In the FMT assay, NHLFs were treated with the pro-fibrotic stimulus TGF-β1, resulting in differentiation of the cells into myofibroblasts which are characterized by expression of ACTA2, secretion of extracellular matrix (ECM) components, such as collagen I and III, and increased migration and contractility (Fig 5A) [27] . Being one of the key players in the TGF-β signaling or control gRNA AdV at total MOI 30 (Cas9:gRNA ratio 1:2), followed by addition of TGF-β1 at DIV 6. Cells were fixed for immunofluorescent labelling of SMAD3 and ACTA2 followed by HCA at DIV 9. Graphs are representing HCA quantification of ACTA2 and SMAD3 immunofluorescent intensities in optimized segmentation masks and are blotted relative to the control (C1). Data points are from triplicate wells (n = 3) and error bars represent standard deviation. Exemplifying images of target protein and nuclear DAPI labelling are shown. (E) Overview of the EMT assay with indicated time points of treatment in days. Change in expression of certain markers is shown, with arrows demonstrating up-or downregulation (upward and downward arrows, respectively). At the end of the assay HCA is performed on FN1 and SMAD3. (F-G) EMT phenotypic assay with HCA on FN1 and SMAD3. Primary HBECs were co-transduced at DIV 1 with Cas9 and either SMAD3 or control gRNA AdV at total MOI 12 (Cas9:gRNA ratio 1:1), followed by addition of a cocktail containing TGF-β1 and TNFα at DIV 6. Cells were fixed and stained as described in panel A, except that staining was performed for FN1 and SMAD3 in this case. Graphs are blotted relative to the control (C1 Adenoviral CRISPR/Cas9 gene inactivation in human primary cells pathway, SMAD3 is involved in inducing the expression of ACTA2 and ECM components [28, 29] . Prior to TGF-β1 stimulation on DIV 6 NHLFs were co-transduced with Cas9 and different gRNA AdV constructs on DIV 1, and ACTA2 and SMAD3 were monitored by HCA at the end of the assay. The MOI used was based on the results shown in Fig 2. Treatment of NHLFs with TGF-β1 alone led to a significant increase in the number of myofibroblasts which is evident from the appearance of ACTA2 expression (S8A Fig) . This increase in ACTA2 was reduced to almost background level by SMAD3-specific gRNAs, but not the control gRNA (Fig 5B) . All three tested SMAD3 gRNAs had a suppressive effect on ACTA2 expression with SMAD3_v39 being the most potent, in agreement with the effect on indel formation (S1A Fig) . Similar results were obtained in two independent experiments. These results suggest that CRISPR/Cas9-mediated SMAD3 KD can inhibit fibroblast to myofibroblast transition in the FMT assay. In addition, SMAD3 nuclear translocation was significantly reduced by SMAD3--specific gRNA, but not the control gRNA (Fig 5C and S2 Fig) . Since nuclear translocation of SMAD3 is required for regulating expression of TGF-β1 target genes, this provides an explanation for the effects seen on ACTA2 expression. As a positive control we also treated cells with Cas9 and gRNAs targeting ACTA2. Two of three tested ACTA2 gRNAs effectively decreased expression of ACTA2 protein in line with indel formation (Fig 5D and S1A Fig) , supporting the relevance of the approach.
Apart from the FMT assay we also applied the AdV CRISPR/Cas9 platform in an EMT assay, using primary HBECs. The EMT assay is based on the transition of epithelial to mesenchymal cells, which is primarily induced by activation of the TGF-β pathway. During this process epithelial cells lose their epithelial phenotype and acquire fibroblast-like properties, as well as increased motility and reduced cell adhesion. Epithelial cells undergoing EMT display decreased expression of epithelial markers (e.g. E-cadherin and ZO-1) and increased expression of mesenchymal markers, such as collagen I and III and FN1 (Fig 5E) [27] . For EMT induction the experimental setup was similar to the FMT assay, except that the cells were stimulated with a cocktail of TGF-β1 and TNFα (tumor necrosis factor alpha), instead of TGF-β1 alone. Treatment of HBECs with TGF-β1 and TNFα together led to an increase in the expression of FN1, a well-established mesenchymal marker downstream of SMAD3 (S8B Fig). Co-TD of HBECs with Cas9 and SMAD3-targeting gRNA led to strong depletion of SMAD3 protein with SMAD3_v39 again being the most potent gRNA (Figs 5F and S1B). The MOI used was based on the results shown in Fig 3. Parallel observations were made for FN1, where the different SMAD3-specific gRNAs showed a similar trend in reducing FN1 expression (Fig 5G) [27] . Comparable results were obtained in two independent experiments. These data indicate a significant inhibition of EMT in HBECs treated with our AdV CRISPR/Cas9 constructs through inactivation of SMAD3 and, as a result, the TGF-β pathway. Thus, AdV delivery of the CRISPR/Cas9 system in human primary cells appears to be efficient and may be a valuable tool for target discovery and/or target validation purposes, which may contribute substantially to the drug discovery process.
Discussion
Drug discovery is in part dependent on the identification and validation of novel targets, which until now has largely relied on the RNAi technology, using siRNA or shRNA to target the mRNA of interest. Since its discovery in the late 1990s, application of this technology in disease-relevant phenotypic assays has led to the identification of many interesting and valid targets in several therapeutic areas. Although RNAi has been shown to be a powerful method, its limitations have also increasingly surfaced. RNAi acts at the post-transcriptional level targeting the mRNA, whereas CRISPR/Cas9 exerts its effects upstream at the genomic DNA level.
As a consequence, CRISPR/Cas9 effects are heritable in dividing cells and may result in amplification of the initial impact, thereby obtaining potentially greater efficiencies when compared to RNAi. While RNAi may have different effects on the transcript variants of its target, CRISPR/Cas9 can lead to KD of all mRNA isoforms from the same gene. Since CRISPR/Cas9 is mechanistically different from RNAi it may also have other unwanted off-target effects. In many cases these off-targets may not be relevant since the majority of the genome is not expressed. Combining the results obtained by using CRISPR/Cas9 with those obtained by RNAi may also assist in identifying specific effects of target KD/KO.
Since the recent first publications on the mechanism of DNA cleavage by the CRISPR/Cas9 system, the application of this RGEN has reached unprecedented levels [8, 30, 31] . The technology is widely applicable, which is illustrated by multiple studies reporting on the generation of genomic editing and KOs in cells, but also in different animal species, ranging from Caenorhabditis elegans and Drosophila to mouse and primates [32] [33] [34] [35] [36] [37] , as well as plants. The main advantage of the CRISPR/Cas9 system compared to other nucleases is the simplicity and low cost of its application. For every different target of interest only the 19-20 nucleotide target specific sequence of the gRNA has to be adjusted, making the CRISPR/Cas9 platform a particularly attractive system for high-throughput purposes. This is different from ZFNs or TALENs, where completely new proteins have to be designed for each different target site.
As CRISPR/Cas9 is present in prokaryotes only, its application in eukaryotes requires introduction of both Cas9 and gRNA into the host. Delivery of these components can be achieved by different means, such as plasmid transfection or viral TD. The latter method clearly has the most potential due to its use in many cell types, including dividing and non-dividing cells, its relatively high delivery efficiency and its application in high-throughput screening. Successful delivery of Cas9 and gRNA by different viral vectors has been reported, such as LVs [10, 11] , adeno-associated virus (AAV) [38] and AdV [39] . However, the AdV delivery method seems to outperform the accuracy of the other available systems when it comes to HDR to establish gene editing [12] . The implementation of CRISPR/Cas9 in human differentiated primary cells has so far been limited to only a few different fully differentiated cell types, including CD4+ T-lymphocytes, dermal fibroblasts, (pre)adipocytes, endothelial cells, and airway epithelial cells [15] [16] [17] [18] [19] . In many of these cases, selection or sorting of edited cells was applied to increase efficiency [19, 40] . Such selection procedures are not always desirable, since they may affect the properties of the primary cells and are time consuming. As target discovery and drug evaluation in such types of cells appears to be most relevant, we were interested to determine whether AdV delivery of the CRISPR/Cas9 system without selection of manipulated cells is of sufficient efficiency to study phenotypic changes in human primary cells. Taking this into account, we have set up an AdVbased CRISPR/Cas9 system to enable target identification and validation for drug discovery.
In this study we demonstrate the power of this system as a proof of principle by focusing on SMAD3, a well-known player in the TGF-β signaling pathway. Our results show highly efficient genomic editing of SMAD3 at the DNA level in two different human primary cell types without enrichment or selection of the edited cell population. Genomic editing increased at higher viral load, but reached a plateau around a total MOI 40 and 20 in the NHLFs and HBECs, respectively. Under these conditions most of the cells should be transduced with AdV and are therefore expected to express Cas9 and gRNA. One advantage of the co-TD system is that it allows varying the ratio between Cas9 and gRNA expression within the cell. This is different from the all-in-one AdV where Cas9 and gRNA ratios are fixed. Direct comparison of TD with a single all-in-one Cas9/gRNA AdV versus co-TD with separate Cas9 and gRNA AdVs revealed, that both strategies work equally well when it comes to genomic editing. These results suggest that the genomic disruption is mainly dependent on the overall concentration of the Cas9-gRNA complex rather than a specific ratio of the endonuclease and gRNA components, which is in line with other reports [39] . The use of a single all-in-one AdV may, however, elicit higher toxicity (S4 and S5 Figs), potentially due to technical aspects of AdV production, and will have to be further improved, but may offer significant advantages over co-TD approaches in the future, in particular for high-throughput screening. Genetic disruption of SMAD3 using the AdV-based CRISPR/Cas9 system led to strongly reduced protein expression, suggesting that the majority of NHEJ-derived indels resulted in protein KO. The depletion of SMAD3 protein inhibited downstream events in the TGF-β signaling cascade, where ACTA2 and FN1 levels were significantly decreased in NHLFs and HBECs, respectively. These results indicate suppression of SMAD3 expression by AdV CRISPR/Cas9 leading to the desired phenotype, i.e. inhibition of FMT/EMT, both of which are processes contributing to the development of fibrosis in vivo. Taken together, the AdV CRISPR/Cas9 platform can be considered an elegant way to study the contribution of genes to the development of a certain disease state and may, therefore, expand the current target discovery and validation toolbox.
As with RNAi, the CRISPR/Cas9 system is expected to have off-target effects, since the guide sequence is only 19-20 nucleotides in length. Reports concerning Cas9 off-targeting have been somewhat contradicting so far. While some studies mention significant off-target mutagenesis, others demonstrate relatively low indel frequencies at unintended genomic regions [41] [42] [43] . It appears that binding of Cas9 to a certain site does not necessarily result in cleavage and, therefore, generation of a DSB. Although binding of Cas9 can be widespread (i.e. varying from 10 to >1000 sites), the vast majority of off-target sites do not appear to be mutated [44, 45] . This is an important finding, since the incidence of off-target mutations should be minimized if one aims at studying gene function or, more importantly, wishes to correct a disease-causing mutation. In the current study we have not investigated off-target effects, which will have to be carried out in future studies to fully evaluate the system.
The effects seen after CRISPR/Cas9-mediated editing of SMAD3 appeared robust in the FMT phenotypic assay, whereas the outcome was less pronounced in the EMT assay. The latter may be due to the relatively low MOI used for TD of the cells. The HBECs were treated with MOI 12 in the actual EMT phenotypic assay to limit unspecific effects in the complex assay and to keep the cells viable (Figs 5F and 5G, S1B and S5A). The lower MOI used in the EMT assay may have yielded less protein KD. As a consequence, fibronectin 1 expression is only moderately affected with about 40% reduction at most in case of treatment with SMAD3_v39 gRNA. Future optimization of the assay will have to address these issues, which could include the use of an all-in-one AdV or the use of purified rather than crude AdV. The FMT phenotypic data appear to show a correlation with the observed SMAD3 indel levels and the resulting effect on protein abundance. In general the SMAD3_v39 gRNA consistently yielded the highest efficiency, both in HBEC and NHLF primary cells. Since the targeted gene disruption leads to prominent downstream inhibition of ACTA2 expression in the FMT assay, it can be concluded that AdV CRISPR/Cas9 efficiently inactivates SMAD3. It should be emphasized again that this effect was achieved without selection or enrichment of Cas9 and/or gRNA expressing or edited cells, which is often performed to increase gene editing efficiency. Therefore, the AdV CRISPR/Cas9 system is expected to offer significant opportunities beside of the current available strategies in drug discovery. The combined use of RNAi and CRISPR/Cas9 for target identification and validation may boost the drug discovery process further and open entire new opportunities. It will be interesting to see what this strategy will bring in the future. transduced with Cas9 and gRNA AdV the ratio of Cas9:gRNA was 1:1 to allow for direct comparison with the all-in-one AdV. NHLFs were harvested at DIV 9 after which genomic DNA was analyzed for the presence of indels by SURVEYOR 1 assay as described earlier. Indel frequencies were quantified as determined by densitometry of the DNA fragments depicted in Fig 2A and 2C. (B) Primary HBECs were treated as in A, except that TD was performed at a maximal total MOI of 40. Indel frequencies were quantified as determined by densitometry of the DNA fragments depicted in Fig 3A and 3C . Cas9+39: co-TD with Cas9 and SMAD3 targeting gRNA; 39 all-in-one: TD with a SMAD3 targeting all-in-one AdV.
Supporting information
(TIFF) S1 Table. Primer and gRNA targeting sequences used in this study. The expected PCR fragments after successful genomic editing detected by SURVEYOR 1 assay are shown. All gRNAs are preceded by a guanine nucleotide (underlined) at the 5' end to promote transcription driven by the U6 promoter. NA: not applicable.
